Ceritinib Is a Novel Triple Negative Breast Cancer Therapeutic Agent

0
209
Combination therapy of Ceritinib and Enzalutamide were investigated using androgen receptor positive breast cancer mouse xenograft models.
[Molecular Cancer]
Full ArticlePress Release